Medical Press Release - Page 2 of 12 - Medika Life : Keeping you informed

Early, in-hospital treatment with colchicine reduces the odds of future cardiovascular problems by 48% in people who have just survived a heart attack

FDA Approves New Opioid, Olinvyk, for Intravenous Use in Hospitals

Medika Life - August 8, 2020

the U.S. Food and Drug Administration approved Olinvyk (oliceridine), an opioid agonist for the management of moderate to severe acute pain in adults

Benchmark KFF Survey: Annual Family Premiums for Employer Coverage Rise 7% to Nearly $24,000 in 2023

Medika Life - November 28, 2023

Amid Changing Abortion Laws, 1-in-10 Large Firms Say Their Largest Plan Doesn’t Cover Legally Provided Abortions Under Any Circumstances

ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis

Medika Life - August 6, 2020

ZEPOSIA, a treatment for multiple sclerosis is the first and only approved sphingosine-1-phosphate (S1P) receptor modulator with no genetic test or first dose observation at initiation

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

CATEGORIES

AI-Driven Model Supports Safer and More Precise Blood Sugar Management After Heart Surgery

Corundum Convergence Institute Launches to Catalyze Funding for Research and Innovation in Neuroscience and Systems Biology

StuffThatWorks and The Marfan Foundation to Engage in Pilot Program

Intellihealth Chief Medical Officer, Dr. Leon Igel, Honored as American Diabetes Association Greater New York Research Dinner Medical Honoree of the Year

LATEST

TRENDING

Medika’s Call for Food Aid for Starving Filipino Children

Lover, the App That Helps Women Reach Orgasm

ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis

The 50 Most Influential Leaders in Pharmacy 2022 Awards

The Nation’s Only Virtual At-Home Detox Programs from Workit Health Expands

SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults Approved

FINN Partners Brings Aboard the Pharmacy Podcast Network

Reblozyl (luspatercept) Approved for Treatment of Transfusion-Dependent Anemia

South University Announces New MSPA Program at West Palm Beach Campus

Parnell Pharmaceuticals Announces Nomovid™ Antiviral Nasal Spray

EDITORS CHOICE

Colchicine Shows 48% Reduction in Future Cardio Issues for Heart Attack Victims

FDA Approves New Opioid, Olinvyk, for Intravenous Use in Hospitals

Benchmark KFF Survey: Annual Family Premiums for Employer Coverage Rise 7% to Nearly $24,000 in 2023

ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis

CONNECT WITH US ON SOCIAL MEDIA

Compliance

CORPORATE & MEDIA

Popular categories